Compare Herbalife Nutrition Ltd (HLF) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Herbalife Nutrition Ltd vs ResMed Inc. — how do they compare? Herbalife Nutrition Ltd trades at $12.18 (market cap $1.25B), while ResMed Inc. trades at $192.97 (market cap $28.40B). The key difference: ResMed Inc. is far larger — about 22.7× Herbalife Nutrition Ltd's market cap, and ResMed Inc. pays a 1.23% dividend while Herbalife Nutrition Ltd pays none. Which is the better fit depends on your goals.
| HLF | RMD | |
|---|---|---|
Market Cap | $1.25B | $28.40B |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $293.73 |
52-Week Low | $7.75 | $182.82 |
Enterprise Value | $2.98B | $27.58B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLF trades at $12.04, up 0.42% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.64, beating expectations of $0.607, and raised full-year guidance. Revenue for 2025 was $5.04 billion with a net income margin of 4.66%, while valuation ratios remain low with a P/E of 5.38 and P/S of 0.25. Recent news includes Herbalife's inclusion in TIME's America's Best Companies 2026 and a $1.45 billion debt refinancing completed in April 2026.
The outlook for HLF is cautiously optimistic due to strong earnings beats and strategic initiatives, but risks include high debt levels and competitive pressures. Analyst consensus is 57.69% buy, with institutional sentiment leaning positive amid ongoing business transformation efforts.
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
